Cargando…
Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
Objective. The aim of this study was to determine whether biologic-free remission of RA is possible with discontinuation of abatacept. Methods. Japanese RA patients in 28-joint DAS with CRP (DAS28-CRP) remission (<2.3) after >2 years of abatacept treatment in a phase II study and its long-term...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372674/ https://www.ncbi.nlm.nih.gov/pubmed/25257039 http://dx.doi.org/10.1093/rheumatology/keu338 |
_version_ | 1782363222315106304 |
---|---|
author | Takeuchi, Tsutomu Matsubara, Tsukasa Ohta, Shuji Mukai, Masaya Amano, Koichi Tohma, Shigeto Tanaka, Yoshiya Yamanaka, Hisashi Miyasaka, Nobuyuki |
author_facet | Takeuchi, Tsutomu Matsubara, Tsukasa Ohta, Shuji Mukai, Masaya Amano, Koichi Tohma, Shigeto Tanaka, Yoshiya Yamanaka, Hisashi Miyasaka, Nobuyuki |
author_sort | Takeuchi, Tsutomu |
collection | PubMed |
description | Objective. The aim of this study was to determine whether biologic-free remission of RA is possible with discontinuation of abatacept. Methods. Japanese RA patients in 28-joint DAS with CRP (DAS28-CRP) remission (<2.3) after >2 years of abatacept treatment in a phase II study and its long-term extension entered this 52 week, multicentre, non-blinded, prospective, observational study. At enrolment, the patients were offered the option to continue abatacept or not. The primary endpoint was the proportion of patients who remained biologic-free at 52 weeks after discontinuation. Clinical, functional and structural outcomes were compared between those who continued and those who discontinued abatacept. Results. Of 51 patients enrolled, 34 discontinued and 17 continued abatacept treatment. After 52 weeks, 22 of the 34 patients (64.7%) remained biologic-free. Compared with the continuation group, the discontinuation group had a similar remission rate (41.2% vs 64.7%, P = 0.144) although they had a significantly higher mean DAS28-CRP score at week 52 (2.9 vs 2.0, P = 0.012). The two groups were also similar with regard to mean HAQ Disability Index (HAQ-DI) score (0.6 for both, P = 0.920), mean change in total Sharp score (ΔTSS; 0.80 vs 0.32, P = 0.374) and proportion of patients in radiographic remission (ΔTSS ≤ 0.5) at the endpoint (64.3% vs 70.6%, P = 0.752). Those attaining DAS28-CRP < 2.3 or < 2.7 without abatacept at the endpoint had significantly lower HAQ-DI score and/or CRP at enrolment. Non-serious adverse events occurred in three patients who continued or resumed abatacept. Conclusion. Biologic-free remission of RA is possible in some patients after attaining clinical remission with abatacept. Lower baseline HAQ-DI or CRP may predict maintenance of remission or low disease activity after discontinuation of abatacept. Trial registration: UMIN Clinical Trials Registry, http://www.umin.ac.jp/ctr/ (UMIN000004137). |
format | Online Article Text |
id | pubmed-4372674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43726742015-03-26 Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan Takeuchi, Tsutomu Matsubara, Tsukasa Ohta, Shuji Mukai, Masaya Amano, Koichi Tohma, Shigeto Tanaka, Yoshiya Yamanaka, Hisashi Miyasaka, Nobuyuki Rheumatology (Oxford) Clinical Science Objective. The aim of this study was to determine whether biologic-free remission of RA is possible with discontinuation of abatacept. Methods. Japanese RA patients in 28-joint DAS with CRP (DAS28-CRP) remission (<2.3) after >2 years of abatacept treatment in a phase II study and its long-term extension entered this 52 week, multicentre, non-blinded, prospective, observational study. At enrolment, the patients were offered the option to continue abatacept or not. The primary endpoint was the proportion of patients who remained biologic-free at 52 weeks after discontinuation. Clinical, functional and structural outcomes were compared between those who continued and those who discontinued abatacept. Results. Of 51 patients enrolled, 34 discontinued and 17 continued abatacept treatment. After 52 weeks, 22 of the 34 patients (64.7%) remained biologic-free. Compared with the continuation group, the discontinuation group had a similar remission rate (41.2% vs 64.7%, P = 0.144) although they had a significantly higher mean DAS28-CRP score at week 52 (2.9 vs 2.0, P = 0.012). The two groups were also similar with regard to mean HAQ Disability Index (HAQ-DI) score (0.6 for both, P = 0.920), mean change in total Sharp score (ΔTSS; 0.80 vs 0.32, P = 0.374) and proportion of patients in radiographic remission (ΔTSS ≤ 0.5) at the endpoint (64.3% vs 70.6%, P = 0.752). Those attaining DAS28-CRP < 2.3 or < 2.7 without abatacept at the endpoint had significantly lower HAQ-DI score and/or CRP at enrolment. Non-serious adverse events occurred in three patients who continued or resumed abatacept. Conclusion. Biologic-free remission of RA is possible in some patients after attaining clinical remission with abatacept. Lower baseline HAQ-DI or CRP may predict maintenance of remission or low disease activity after discontinuation of abatacept. Trial registration: UMIN Clinical Trials Registry, http://www.umin.ac.jp/ctr/ (UMIN000004137). Oxford University Press 2015-04 2014-09-24 /pmc/articles/PMC4372674/ /pubmed/25257039 http://dx.doi.org/10.1093/rheumatology/keu338 Text en © The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Science Takeuchi, Tsutomu Matsubara, Tsukasa Ohta, Shuji Mukai, Masaya Amano, Koichi Tohma, Shigeto Tanaka, Yoshiya Yamanaka, Hisashi Miyasaka, Nobuyuki Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan |
title | Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan |
title_full | Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan |
title_fullStr | Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan |
title_full_unstemmed | Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan |
title_short | Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan |
title_sort | biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in japan |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372674/ https://www.ncbi.nlm.nih.gov/pubmed/25257039 http://dx.doi.org/10.1093/rheumatology/keu338 |
work_keys_str_mv | AT takeuchitsutomu biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan AT matsubaratsukasa biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan AT ohtashuji biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan AT mukaimasaya biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan AT amanokoichi biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan AT tohmashigeto biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan AT tanakayoshiya biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan AT yamanakahisashi biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan AT miyasakanobuyuki biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan |